Seeking Alpha

NuVasive (NUVA +13%) moves up after beating on its Q3 bottom and top line numbers today. The...

NuVasive (NUVA +13%) moves up after beating on its Q3 bottom and top line numbers today. The company lowers guidance going forward, now expecting FY12 revenue of between $601M to $606M on earnings of $0.88 to $0.90 per share. However, the company also noted that it's aggressively moving to replenish its diminished salesforce that led to flat third-quarter sales growth in its spinal division.

Check out Seeking Alpha’s new Earnings Center »

Comments (1)
  • anil92691
    , contributor
    Comments (416) | Send Message
     
    Nuvasive should spend some money on lobbyists to stop orthopedic surgeons from starting marketing companies and using the products marketed on their patients. This conflict of interest is awful for patients and pricing. The Sunshine Act's objective is to stop this conflict of interest. However it has to be seen if this helps.
    24 Oct 2012, 05:16 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs